ALX Oncology Holdings Inc. - Common Stock (ALXO)

Competitors to ALX Oncology Holdings Inc. - Common Stock (ALXO)

Blueprint Medicines Corporation 

Blueprint Medicines Corporation specializes in developing targeted therapies for genomically defined cancers, rare diseases, and cancers with significant unmet medical need. Their focus on genetic profiling and precision medicine creates competition with ALX Oncology, particularly in how both companies position their therapies against specific cancer types. However, Blueprint's established partnerships and broader pipeline provide them with a competitive advantage in the market.

Mirati Therapeutics

Mirati Therapeutics focuses on targeted therapies for cancer treatment, including KRAS inhibitors that could be seen as a direct competition to ALX Oncology's immuno-oncology approaches. Both companies aim to innovate in the oncology space by developing treatments that harness the immune system, but Mirati's advanced pipeline and strategic partnerships grant them a strong competitive edge in terms of research funding and market presence.

NantKwest Inc.

NantKwest Inc. is involved in developing and commercializing therapies utilizing natural killer (NK) cells to combat cancer, standing in contrast to ALX Oncology's more traditional pathways. While this approach is innovative and offers an alternative immunotherapy route, ALX has a more clear focus on monoclonal antibodies, which could present competitive advantages in specific therapeutic areas. However, NantKwest's novel approach and ongoing clinical trials suggest they are carving out a significant niche.

TCR2 Therapeutics

TCR2 Therapeutics develops T-cell therapies aimed at cancer treatment, presenting a distinct approach to immunotherapy compared to ALX Oncology's focus on monoclonal antibodies. While both aim to leverage the immune system to fight cancer, TCR2's unique modalities and growing clinical data might give them a competitive edge in garnering investor interest and navigating regulatory approvals.